PRMS
MCID: PRG090
MIFTS: 34

Progressive Relapsing Multiple Sclerosis (PRMS)

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Progressive Relapsing Multiple Sclerosis

MalaCards integrated aliases for Progressive Relapsing Multiple Sclerosis:

Name: Progressive Relapsing Multiple Sclerosis 12 15
Multiple Sclerosis, Progressive Relapsing 71
Progressive-Relapsing Ms 12
Prms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050785
SNOMED-CT 67 724778008
UMLS 71 C0393666

Summaries for Progressive Relapsing Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by steadily worsening symptoms and attacks during periods of remission with disease progression from the onset.

MalaCards based summary : Progressive Relapsing Multiple Sclerosis, also known as multiple sclerosis, progressive relapsing, is related to encephalitis and dengue virus. An important gene associated with Progressive Relapsing Multiple Sclerosis is FCN1 (Ficolin 1), and among its related pathways/superpathways are Innate Immune System and Complement and coagulation cascades. The drugs Testosterone and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and heart.

Related Diseases for Progressive Relapsing Multiple Sclerosis

Diseases related to Progressive Relapsing Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Related Disease Score Top Affiliating Genes
1 encephalitis 10.8
2 dengue virus 10.7
3 japanese encephalitis 10.7
4 west nile virus 10.6
5 pulmonary aspergilloma 10.5 FCN3 FCN1
6 tick-borne encephalitis 10.5
7 borderline leprosy 10.4 MASP2 FCN2
8 vaccinia 10.4
9 sporotrichosis 10.4 MBL2 MASP2
10 anti-basement membrane glomerulonephritis 10.4 CFHR2 CCR6
11 complement component 3 deficiency 10.3 MBL2 MASP1 CFHR2
12 hereditary angioedema 10.3 MBL2 MASP2 MASP1
13 meningococcal meningitis 10.3 MBL2 CFHR2
14 yellow fever 10.3
15 rheumatic heart disease 10.3 MBL2 FCN3 FCN2 FCN1
16 mannose-binding lectin deficiency 10.3 MBL2 MASP2 FCN3 FCN1
17 learning disability 10.2 MASP1 COLEC11 COLEC10
18 scabies 10.2 MBL2 CCR6
19 murray valley encephalitis 10.2
20 dengue disease 10.2
21 spinal cord injury 10.2
22 epididymo-orchitis 10.2 TNP2 TNP1
23 invasive aspergillosis 10.2 PTX3 MBL2 CCR6
24 aspergillosis 10.2 PTX3 MBL2 CCR6
25 listeriosis 10.2 MBL2 IFNB1 CCR6
26 coronavirus infectious disease 10.2 MBL2 IFNB1 CCR6
27 helix syndrome 10.2
28 scoliosis 10.2
29 covid-19 10.2
30 dengue hemorrhagic fever 10.2
31 brain injury 10.2
32 spasticity 10.2
33 coccidioidomycosis 10.2 MBL2 CCR6
34 central nervous system vasculitis 10.2 PTX3 CCR6
35 primary bacterial infectious disease 10.2 IFNB1 CFHR2 CCR6
36 rheumatic fever 10.1 MBL2 MASP2 FCN3 FCN2 FCN1
37 endometrial cancer 10.1
38 microcephaly 10.1
39 poliomyelitis 10.1
40 severe combined immunodeficiency 10.1
41 back pain 10.1
42 chronic pain 10.1
43 candidiasis 10.1 MBL2 CCR6 APCS
44 retinal vasculitis 10.0 IFNB1 CCR6
45 bacterial infectious disease 10.0 PTX3 MBL2 IFNB1 CCR6
46 leiomyoma, uterine 9.9
47 osteoporosis 9.9
48 polykaryocytosis inducer 9.9
49 triiodothyronine receptor auxiliary protein 9.9
50 anemia, autoimmune hemolytic 9.9

Graphical network of the top 20 diseases related to Progressive Relapsing Multiple Sclerosis:



Diseases related to Progressive Relapsing Multiple Sclerosis

Symptoms & Phenotypes for Progressive Relapsing Multiple Sclerosis

Drugs & Therapeutics for Progressive Relapsing Multiple Sclerosis

Drugs for Progressive Relapsing Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
2 Hormone Antagonists Phase 4
3 Hormones Phase 4
4 Androgens Phase 4
5 Vaccines Phase 1, Phase 2
6 Immunologic Factors Phase 1, Phase 2
7 interferons Phase 2
8 Adjuvants, Immunologic Phase 2
9 Mitogens Phase 2
10 Interferon-gamma Phase 2
11 Anti-Inflammatory Agents Phase 2
12
Evening primrose oil Investigational, Nutraceutical Phase 2 308064-97-3
13
Simvastatin Approved Phase 1 79902-63-9 54454
14 Hypolipidemic Agents Phase 1
15 Lipid Regulating Agents Phase 1
16 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1
17 Anticholesteremic Agents Phase 1
18 Antimetabolites Phase 1
19 (T,G)-A-L
20
Glatiramer Acetate 147245-92-9 3081884
21 Trace Elements
22 Vitamins
23 Micronutrients
24 Anti-Retroviral Agents

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly Completed NCT00018356 Phase 4 testosterone
2 Autologous T Cell Vaccination With Line Specific for 9 Myelin Peptides in Patients With Progressive / Relapsing Multiple Sclerosis Completed NCT01448252 Phase 1, Phase 2
3 A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS Terminated NCT01037907 Phase 2 Pleneva TM BGC20-0134;Placebo
4 A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis Completed NCT00813969 Phase 1
5 Double-blinded, Randomized Controlled Trial of Simvastatin Use As Adjuvant Therapy in Relapsing-Remitting Multiple Sclerosis Not yet recruiting NCT04178980 Phase 1 Simvastatin in relapsing remitting multiple sclerosis
6 Current Access to, Use and Perceived Efficacy of Physiotherapy and Rehabilitation Services by People With Progressive Multiple Sclerosis: a Survey of People With Progressive Multiple Sclerosis Via the UK MS Register. Completed NCT02559765
7 Pilot Study for Evaluation of Glatiramer Acetate in RRMS Patients With Comorbid Autoimmune Conditions Completed NCT01456416
8 Functional Assessment Screening Tablets - Patient Reported Measures Translating Research Into Practice Pilot Completed NCT01080183
9 Wahls Paleo Diet and Progressive Multiple Sclerosis Completed NCT01915433
10 Evaluation of Effectiveness of Pharmaceutical Care on the Adherence of HIV-Positive Patients to Antiretroviral Therapy - Randomized Clinical Trial Completed NCT00959361
11 Multiple Sclerosis Registry in Argentina (RelevarEM) Recruiting NCT03375177

Search NIH Clinical Center for Progressive Relapsing Multiple Sclerosis

Genetic Tests for Progressive Relapsing Multiple Sclerosis

Anatomical Context for Progressive Relapsing Multiple Sclerosis

MalaCards organs/tissues related to Progressive Relapsing Multiple Sclerosis:

40
T Cells, Bone, Heart

Publications for Progressive Relapsing Multiple Sclerosis

Articles related to Progressive Relapsing Multiple Sclerosis:

(show all 40)
# Title Authors PMID Year
1
Epidemiology of multiple sclerosis in Santiago de Compostela (Spain). 61
32392359 2020
2
Multiple sclerosis in a multi-ethnic population from Northern California: a retrospective analysis, 2010-2016. 61
32354354 2020
3
Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population. 61
32064117 2020
4
Palliative care interventions for people with multiple sclerosis. 61
31637711 2019
5
Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis. 61
30975397 2019
6
Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009? 61
30815276 2019
7
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. 61
30083762 2018
8
A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis. 61
28365299 2017
9
Multiple sclerosis - etiology and diagnostic potential. 61
28665284 2017
10
Determining Multiple Sclerosis Phenotype from Electronic Medical Records. 61
27882837 2016
11
Bone metabolism and vitamin D status in patients with multiple sclerosis. 61
27375138 2016
12
Recurrent refrains in a patient with multiple sclerosis: Earworms or musical hallucinations? 61
25878018 2014
13
New multiple sclerosis phenotypic classification. 61
25278115 2014
14
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. 61
23841877 2013
15
Teriflunomide for multiple sclerosis. 61
23235682 2012
16
Progressive multiple sclerosis: characteristics and management. 61
21439451 2011
17
Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. 61
20067515 2010
18
[Mitoxantrone for the treatment of patients with multiple sclerosis]. 61
19514518 2009
19
Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. 61
18687447 2008
20
Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. 61
18694542 2008
21
Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. 61
17579804 2007
22
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. 61
17692727 2007
23
Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS). 61
16764339 2006
24
Management of worsening multiple sclerosis with mitoxantrone: a review. 61
16750460 2006
25
Complementary and alternative medicine use in veterans with multiple sclerosis: Prevalence and demographic associations. 61
16847776 2006
26
Mitoxantrone for multiple sclerosis. 61
16235298 2005
27
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. 61
15834643 2005
28
History of modern multiple sclerosis therapy. 61
16170498 2005
29
Mitoxantrone for multiple sclerosis in clinical practice. 61
15623666 2004
30
Current approved options for treating patients with multiple sclerosis. 61
15623672 2004
31
Mechanism of action of mitoxantrone. 61
15623664 2004
32
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. 61
15596747 2004
33
[Immunomodulatory therapy in multiple sclerosis]. 61
15662768 2004
34
Clinical characteristics of progressive relapsing multiple sclerosis. 61
15327045 2004
35
Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. 61
15218811 2004
36
Mitoxantrone: a review of its use in multiple sclerosis. 61
15089110 2004
37
[Diagnosis and treatment of multiple sclerosis. Update, 2003]. 61
14579493 2003
38
A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. 61
12749517 2003
39
Contemporary immunomodulatory therapy for multiple sclerosis. 61
11756861 2001
40
Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. 61
10488816 1999

Variations for Progressive Relapsing Multiple Sclerosis

Expression for Progressive Relapsing Multiple Sclerosis

Search GEO for disease gene expression data for Progressive Relapsing Multiple Sclerosis.

Pathways for Progressive Relapsing Multiple Sclerosis

Pathways related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 PTX3 MBL2 MASP2 MASP1 IFNB1 FCN3
2 11.62 MBL2 MASP2 MASP1 CFHR2
3
Show member pathways
11.55 MBL2 MASP2 MASP1 FCN3 FCN2
4 11.53 MBL2 MASP2 MASP1
5
Show member pathways
11.39 MBL2 MASP2 MASP1 FCN3 FCN2 FCN1
6
Show member pathways
11.34 MBL2 MASP2 MASP1

GO Terms for Progressive Relapsing Multiple Sclerosis

Cellular components related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 PTX3 MBL2 MASP2 MASP1 IFNB1 FCN3
2 chromosome GO:0005694 9.77 TNP2 TNP1 PRM3 PRM2 H1-7
3 collagen-containing extracellular matrix GO:0062023 9.72 MBL2 FCN3 FCN2 FCN1 APCS
4 extracellular space GO:0005615 9.7 PTX3 MBL2 MASP2 MASP1 IFNB1 FCN3
5 blood microparticle GO:0072562 9.58 FCN3 FCN2 APCS
6 nucleosome GO:0000786 9.56 TNP2 TNP1 PRM3 PRM2
7 collagen trimer GO:0005581 9.1 MBL2 FCN3 FCN2 FCN1 COLEC11 COLEC10

Biological processes related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.06 TNP2 TNP1 PRM3 PRM2 H1-7 COLEC11
2 immune system process GO:0002376 10.04 MBL2 MASP2 MASP1 FCN3 FCN2 FCN1
3 spermatogenesis GO:0007283 9.97 TNP2 TNP1 PRM3 PRM2 H1-7
4 innate immune response GO:0045087 9.81 PTX3 MBL2 MASP2 MASP1 FCN3 FCN2
5 chromosome condensation GO:0030261 9.69 PRM3 PRM2 H1-7
6 positive regulation of protein processing GO:0010954 9.58 TNP2 TNP1
7 spermatogenesis, exchange of chromosomal proteins GO:0035093 9.56 TNP2 TNP1
8 negative regulation of viral entry into host cell GO:0046597 9.56 PTX3 FCN3 FCN1 APCS
9 complement activation GO:0006956 9.56 MBL2 MASP2 MASP1 FCN3 FCN2 FCN1
10 negative regulation of viral process GO:0048525 9.55 MBL2 APCS
11 negative regulation by host of viral process GO:0044793 9.54 PTX3 APCS
12 opsonization GO:0008228 9.54 PTX3 MBL2 FCN2
13 spermatid nucleus elongation GO:0007290 9.52 TNP1 H1-7
14 recognition of apoptotic cell GO:0043654 9.5 FCN3 FCN2 FCN1
15 negative regulation of glycoprotein metabolic process GO:1903019 9.48 PTX3 APCS
16 negative regulation of exo-alpha-sialidase activity GO:1903016 9.46 PTX3 APCS
17 negative regulation by host of viral glycoprotein metabolic process GO:0044871 9.43 PTX3 APCS
18 negative regulation by host of viral exo-alpha-sialidase activity GO:0044869 9.4 PTX3 APCS
19 complement activation, lectin pathway GO:0001867 9.23 MBL2 MASP2 MASP1 FCN3 FCN2 FCN1

Molecular functions related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen binding GO:0003823 9.61 FCN3 FCN2 FCN1
2 monosaccharide binding GO:0048029 9.4 COLEC11 COLEC10
3 virion binding GO:0046790 9.37 PTX3 APCS
4 mannose binding GO:0005537 9.33 MBL2 COLEC11 COLEC10
5 complement component C1q binding GO:0001849 9.32 PTX3 APCS
6 carbohydrate derivative binding GO:0097367 9.26 FCN2 FCN1
7 calcium-dependent protein binding GO:0048306 9.26 MBL2 MASP2 MASP1 FCN2
8 carbohydrate binding GO:0030246 9.17 MBL2 FCN3 FCN2 FCN1 COLEC11 COLEC10

Sources for Progressive Relapsing Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....